Lyell Immunopharma (LYEL) Other Non-Current Assets (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Other Non-Current Assets data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 6.04% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 6.04% YoY), and the FY2025 full-year result was $1.6 million, down 65.71% from the prior year.
• Other Non-Current Assets held at $1.6 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $4.6 million in Q4 2024 to a low of $279000.0 in Q1 2022.
• A 5-year average of $983411.8 and a median of $286000.0 in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets jumped 1527.46% in 2024 and slumped 65.71% in 2025, its largest moves.
• Tracing LYEL's Other Non-Current Assets over 5 years: stood at $280000.0 in 2022, then rose by 1.43% to $284000.0 in 2023, then jumped by 1527.46% to $4.6 million in 2024, then tumbled by 65.71% to $1.6 million in 2025, then advanced by 0.06% to $1.6 million in 2026.
• Business Quant data shows LYEL's Other Non-Current Assets at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $2.5 million in Q3 2025.